Lucatumumab is one such example that has been found to be well tolerated,36 at least in moderate and intermediate strength doses.37 Importantly, it has also been shown to prevent induction of NF-κB activity in multiple myeloma cells.38 This strategy would need to be modified for the treatment of diabetes though, as immune cell interactions with the Fc region of cell-bound lucatumumab could potentially lead to either opsonisation of β-cells or antibody-dependent cell cytotoxicity. The gene discussed is NFKB1; the disease is plasma cell myeloma.